" class="no-js "lang="en-US"> Lantern Pharma - Medtech Alert
Thursday, March 28, 2024
Lantern Pharma | Pharmtech Focus

Lantern Pharma

About Lantern Pharma

Lantern Pharma

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Related Story

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

June 12 2023

Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]

Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

March 29 2023

Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning […]

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

January 19 2022

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations

October 28 2021

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]